國家衛生研究院 NHRI:Items for Author

Year

Loading year class tree, please wait....

Items for Author "Oh, DY"

Return to Browse by Author

Showing 30 items.

Collection	Date	Title	Relation
[陳立宗] 會議論文/會議摘要	2022-11	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	-
[陳立宗] 會議論文/會議摘要	2022-09	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	-
[陳立宗] 會議論文/會議摘要	2022-02-01	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1	-
[陳立宗] 會議論文/會議摘要	2021-09	INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)	-
[陳立宗] 會議論文/會議摘要	2020-09	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer	-
[陳立宗] 會議論文/會議摘要	2020-09	Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study	-
[陳立宗] 會議論文/會議摘要	2020-02	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study	-
[陳立宗] 會議論文/會議摘要	2019-10	A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1	-
[陳立宗] 會議論文/會議摘要	2019-02	A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC)	-
[陳立宗] 會議論文/會議摘要	2019-02	A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements	-
[陳立宗] 會議論文/會議摘要	2018-11	M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype	-
[陳立宗] 會議論文/會議摘要	2018-10	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial	-
[陳立宗] 期刊論文	2024-08-20	Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri	-
[陳立宗] 期刊論文	2024-08-06	Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer	-
[陳立宗] 期刊論文	2024-08	Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study	-
[陳立宗] 期刊論文	2023-11	Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer	-
[陳立宗] 期刊論文	2023-01-19	Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma	-
[陳立宗] 期刊論文	2022-02	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr	-
[陳立宗] 期刊論文	2022-01	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study	-
[陳立宗] 期刊論文	2021-10	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study	-
[陳立宗] 期刊論文	2021-07	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab	-
[陳立宗] 期刊論文	2020-05	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data	-
[陳立宗] 期刊論文	2020-05	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer	-
[陳立宗] 期刊論文	2020-02	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study	-
[陳立宗] 期刊論文	2020-01	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer	-
[陳立宗] 期刊論文	2018-01	Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma	-
[陳立宗] 期刊論文	2017-12	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial	-
[陳立宗] 期刊論文	2017-10	Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review	-
[陳立宗] 期刊論文	2017-08	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo	-
[陳立宗] 期刊論文	2015-07	Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review	-

Loading...

Category

Year

Items for Author "Oh, DY"